Short hairpin-looped oligodeoxynucleotides reduce hepatitis C virus replication

Virology Journal

Karin Moelling¹  Felix Broecker² 

[1] Heinrich Pette Institute, Department of Virology, Martini Street 52, D-20251, Hamburg, Germany;Max Planck Institute of Colloids and Interfaces, Department Biomolecular Systems c/o Free University of Berlin, Arnimallee 22, D-14195, Berlin, Germany

关键词: Antiviral therapy;    Broad inhibitor;    ODN;    Oligodeoxynucleotide;    Replicon;    Hepatitis;    HCV;   

Others  :  1154351
DOI  :  10.1186/1743-422X-9-134

 received in 2012-02-28, accepted in 2012-07-23,  发布年份 2012

【 摘 要 】

Background

Persistent infection with hepatitis C virus (HCV) is a leading cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Standard therapy consists of a combination of interferon-alpha and ribavirin, but many patients respond poorly, especially those infected with HCV genotypes 1 and 4. Furthermore, standard therapy is associated with severe side-effects. Thus, alternative therapeutic approaches against HCV are needed.

Findings

Here, we studied the effect of a new class of antiviral agents against HCV, short, partially double-stranded oligodeoxynucleotides (ODNs), on viral replication. We targeted the 5’ nontranslated region (5’ NTR) of the HCV genome that has previously been shown as effective target for small interfering RNAs (siRNAs) in vitro. One of the investigated ODNs, ODN 320, significantly and efficiently reduced replication of HCV replicons in a sequence-, time- and dose-dependent manner. ODN 320 targets a genomic region highly conserved among different HCV genotypes and might thus be able to inhibit a broad range of genotypes and subtypes.

Conclusions

ODNs provide an additional approach for inhibition of HCV, might be superior to siRNAs in terms of stability and cellular delivery, and suitable against HCV resistant to standard therapy. This study underlines the potential of partially double-stranded ODNs as antiviral agents.

【 授权许可】

   
2012 Broecker and Moelling; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Poynard T, Yuen MF, Ratziu V, Lai CL: Viral hepatitis C. Lancet 2003, 362:2095-2100.
• [2]Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M: Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989, 244:359-362.
• [3]Van Regenmortel MHV, Fauquet CM, Bishop DHL, Carstens EB, Estes MK, Lemon SM, Maniloff J, Mayo MA, McGeock DJ, Pringle CR, Wickner RB: Virus taxonomy: the VIIth report of the international committee on taxonomy of viruses. Academic, San Diego, California; 2000.
• [4]Kuiken C, Simmonds P: Nomenclature and numbering of the hepatitis C virus. Methods Mol Biol 2009, 510:33-53.
• [5]Lohmann V, Roos A, Körner F, Koch JO, Bartenschlager R: Biochemical and structural analysis of the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. J Viral Hepat 2000, 7:167-174.
• [6]McHutchison JG, Fried MW: Current therapy for hepatitis C: pegylated interferon and ribavirin. Clin Liver Dis 2003, 7:149-161.
• [7]Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
• [8]El Makhzangy H, Esmat G, Said M, Elraziky M, Shouman S, Refai R, Rekacewicz C, Gad RR, Vignier N, Abdel-Hamid M, Zalata K, Bedossa P, Pol S, Fontanet A, Mohamed MK: Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4. J Med Virol 2009, 81:1576-1583.
• [9]Moelling K, Abels S, Jendis J, Matskevich A, Heinrich J: Silencing of HIV by hairpin-loop-structured DNA oligonucleotide. FEBS Lett 2006, 580:3545-3550.
• [10]Matskevich AA, Ziogas A, Heinrich J, Quast SA, Moelling K: Short partially double-stranded oligodeoxynucleotide induces reverse transcriptase/RNase H-mediated cleavage of HIV RNA and contributes to abrogation of infectivity of virions. AIDS Res Hum Retroviruses 2006, 22:1220-1230.
• [11]Heinrich J, Mathur S, Matskevich AA, Moelling K: Oligonucleotide-mediated retroviral RNase H activation leads to reduced HIV-1 titer in patient-derived plasma. AIDS 2009, 23:213-221.
• [12]Falkenhagen A, Heinrich J, Moelling K: Short hairpin-loop-structured oligodeoxynucleotides reduce HSV-1 replication. Virol J 2009, 6:43. BioMed Central Full Text
• [13]Heinrich J, Schols D, Moelling K: A short hairpin loop-structured oligodeoxynucleotide targeting the virion-associated RNase H of HIV inhibits HIV production in cell culture and in huPBL-SCID mice. Intervirology 2011, 55:242-246.
• [14]Matzen K, Elzaouk L, Matskevich AA, Nitzsche A, Heinrich J, Moelling K: RNase H-mediated retrovirus destruction in vivo triggered by oligodeoxynucleotides. Nat Biotechnol 2007, 25:669-674.
• [15]Kwok T, Helfer H, Alam MI, Heinrich J, Pavlovic J, Moelling K: Inhibition of influenza A virus replication by short double-stranded oligodeoxynucleotides. Arch Virol 2009, 154:109-114.
• [16]Noreen F, Heinrich J, Moelling K: Antitumor activity of small double-stranded oligodeoxynucleotides targeting telomerase RNA in malignant melanoma cells. Oligonucleotides 2009, 19:169-178.
• [17]Kanda T, Steele R, Ray R, Ray RB: Small interfering RNA targeted to hepatitis C virus 5’ nontranslated region exerts potent antiviral effect. J Virol 2007, 81:669-676.
• [18]Chevalier C, Saulnier A, Benureau Y, Fléchet D, Delgrange D, Colbère-Garapin F, Wychowski C, Martin A: Inhibition of hepatitis C virus infection in cell culture by small interfering RNAs. Mol Ther 2007, 15:1454-1462.
• [19]Krönke J, Kittler R, Buchholz F, Windisch MP, Pietschmann T, Bartenschlager R, Frese M: Alternative approaches for efficient inhibition of hepatitis C virus RNA replication by small interfering RNAs. J Virol 2004, 78:3436-3446.
• [20]Tang JY, Temsamani J, Agrawal S: Self-stabilized antisense oligodeoxynucleotide phosphorothioates: properties and anti-HIV activity. Nucleic Acids Res 1993, 21:2729-2735.
• [21]Lohmann V, Koch JO, Herian U, Theilmann L, Bartenschlager R: Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999, 285:110-113.
• [22]Berger KL, Randall G: Possibilities for RNA interference in developing hepatitis C virus therapeutics. Viruses 2010, 2:1647-1665.
• [23]Moelling K, Matskevich A, Jung JS: Relationship between retroviral replication and RNA interference machinieries. Cold Spring Harb Symp Quant Biol 2006, 71:365-368.
• [24]Chan JH, Lim S, Wong WS: Antisense oligonucleotides: from design to therapeutic application. Clin Exp Pharmacol Physiol 2006, 33:533-540.
• [25]Kwok T, Heinrich J, Jung-Shiu J, Meier MG, Mathur S, Moelling K: Reduction of gene expression by a hairpin-loop structured oligodeoxynucleotide: alternative to siRNA and antisense. Biochim Biophys Acta 2009, 1790:1170-1178.